PRDX2 and acute myeloid leukemia: Notably, post-therapy AML cells from patients who achieved partial remission (P116 and P105) displayed activation of response to reactive oxygen species (PRDX2, BTK, NRIP1) and heme metabolism signaling pathways (HBB, HBA1, HBA2) compared to the pre-therapy populations (Fig. 4f, g).